Evidence map›Paper›PMID 42333701›Full record

ArticleJournal of medical virology2026

Broadly Protective Antibody-Like Vaccines Against Highly Pathogenic Coronaviruses.

Assala Helal, Najwa D Aljehani, Aishah Ghazwani, Reem M Alsulaiman, Faris Alyami, Wesam H Abdulaal, Asem Alsharef, Maimonah Alghanmi, Ayat Zawawi, Ala A Azhari and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Assala HelalVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Najwa D AljehaniVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Aishah GhazwaniVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0001-7576-8418
Reem M AlsulaimanVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Faris AlyamiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Wesam H AbdulaalDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Asem AlsharefVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Maimonah AlghanmiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Ayat ZawawiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Ala A AzhariVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Afnan AlmehmadiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Jood BalulaVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Tarfa AltorkiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0009-0001-0374-2187
Rowa Y AlhabbabVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Muhammad Yasir KhanVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Khalid AlluhaybiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0002-5554-6671
Aisha AlnamiVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Thikryat NeamatallahDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Turki S AbujamelVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0001-9503-8770
Mohamed A AlfalehVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Anwar M HashemVaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0002-8471-7011

Funding

Jameel Fund for Infectious Disease Research and Innovation JML: 005-141-2024
6 · The paper itself

Abstract

SARS-CoV-2 and MERS-CoV are highly pathogenic and contagious coronaviruses. Despite intensive vaccination, SARS-CoV-2 continues to spread, and no FDA-approved vaccines exist for MERS-CoV; thus, more effective and safer vaccine options are needed. The receptor-binding domain (RBD) of coronaviruses is a primary target of neutralizing antibodies (nAbs); therefore, we generated three bivalent IgG1 Fc-fusion vaccines (BiVaxs) combining SARS-CoV-2 and MERS-CoV RBDs. The BiVax

Indexed as

Antibodies, ViralCOVID-19COVID-19 VaccinesMiddle East Respiratory Syndrome CoronavirusSARS-CoV-2Viral VaccinesAnimalsAntibodies, NeutralizingFemaleHumansImmunoglobulin GMiceSevere acute respiratory syndrome-related coronavirusSpike Glycoprotein, CoronavirusVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, CoronavirusVaccines, SyntheticViral VaccinesantibodiescoronavirusesFc‐fusionMERS‐CoVSARS‐CoV‐2vaccines

Identifiers

PMID42333701
PMCPMC13287912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.